Arthneeti
NF

NGL Fine Chem Ltd

Q3 FY25Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd Q3 FY25 Results & Presentation Highlights: Revenue ₹89.10 Cr, PAT ₹1.28 Cr

Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.

Price₹2,895
Market cap₹1.7K Cr
P/E33.9
Updated24 Sept 2026
Read3 min read

Based on NGL Fine Chem Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Q3FY25 EBITDA: ₹5.10 Crores, down 63.25% YoY - Q3FY25 EBITDA Margin: 5.72%, down 1005 bps YoY - Q3FY25 Profit After Tax (PAT): ₹1.28 Crores, down 87.28% YoY - No explicit margin outlook is provided in the presentation.

From NGL Fine Chem Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8).
  • Total income for Q3FY25: ₹88.97 crores, down 2.91% Y-o-Y (Page 8).
  • EBITDA for Q3FY25 was ₹5.10 crores, a sharp Y-o-Y decline of 63.25% (Page 8).
  • Quarterly operational metrics show segmental revenue mix for Q3FY25 as: Animal API 93%, Human API 2%, Intermediates 2%, Formulations 3% (Page 7).
  • Management commentary notes a revenue decline driven by lower demand due to fewer disease outbreaks in key markets, pricing pressure (~8-10% realization decline), and currency challenges in African markets (Page 6).

2 more points management made on revenue & sales performance

Profitability & Margins

See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Brownfield Expansion:
  • Ongoing initiative to increase capacities to meet growing demand.
  • Greenfield Expansion at Tarapur:
  • Completed expansion in subsidiary Macrotech.
  • Additional capacities of intermediates with commercial production started.
  • 50% capacity expansion to meet demand for new products in pipeline.
  • Estimated capex of ₹160 Crores.
  • Funded through debt and internal accrual.
  • Civil construction ongoing; ₹80.59 Crores invested till Q3FY25.
  • Phase 1 of CAPEX project slated for completion in current quarter (Q4FY25).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation for NGL Fine-Chem Limited does not explicitly report any details regarding: - Order book size - Order inflow figures - Pending orders or backlog None of these terms or related metrics appear in the provided pages of the presentation. The focus is on financial performance, operational metrics, manufacturing capacity, and strategic initiatives without mention of current or future order status.

NGL Fine Chem Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹145 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt Ltd (Q3 FY25)

    725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key investor presentation takeaways from Wockhardt Ltd's Q3 FY25 investor presen

  • Shree Ganesh Remedies Ltd (Q3 FY25)

    Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 investor presentation — and how it ra

  • Themis Medicare Ltd (Q3 FY25)

    93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY25 investor presentation — and how i

  • Lincoln Pharmaceuticals Ltd (Q3 FY25)

    EBITDA:** ₹32.2 crore, up 16% year-on-year. Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q3 FY25 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were NGL Fine Chem Ltd Q3 FY25 results?

Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Q3FY25 EBITDA: ₹5.10 Crores, down 63.25% YoY - Q3FY25 EBITDA Margin: 5.72%, down 1005 bps YoY - Q3FY25 Profit After Tax (PAT): ₹1.28 Crores, down 87.28% YoY - No explicit margin outlook is provided in the presentation.

What is NGL Fine Chem Ltd share price analysis?

NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.

Is NGL Fine Chem Ltd planning capital expenditure?

Brownfield Expansion: - Ongoing initiative to increase capacities to meet growing demand.

Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.